Title |
Interaction of active compounds from Aegle marmelos CORREA with histamine-1 receptor
|
Authors |
Agung Endro Nugroho1*, Dany Dwi Agistia1, Maulana Tegar2 & Hari Purnomo2
|
Affiliation |
1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta Indonesia; 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta Indonesia |
|
agungendronugroho@yahoo.com; *Corresponding author |
Article Type |
Hypothesis |
Date |
Received April 05, 2013; Accepted April 06, 2013; Published April 30, 2013
|
Abstract |
The aim of this study is to determine the affinity of six active compounds of Aegle Marmelos Correa, they are (E, R)-Marmin, skimmianine, (S)-aegeline, aurapten, zeorin, and dustanin as antihistamines in histamine H1 receptor in comparison to cetirizin, diphenhydramine and chlorpheniramine as ligands comparison. Previously, in the in vitro study marmin obviously antagonized the histamine H1 receptor in a competitive manner. Methods: molecular docking to determine the interaction of ligand binding to its receptor. Lower docking score indicates more stable binding to that protein. Results: Marmin, skimmianine, aegeline, aurapten, zeorin, and dustanin were potential to develop as antihistamine agents, especially as histamine H1 receptor antagonists by interacting with amino acid residues, Asp107, Lys179, Lys191, Asn198, and Trp428 of histamine H1 receptor. Conclusions: Based on molecular docking, Amino acid residues involved in ligand protein interactions were Asp107, Lys179, Lys191, Asn198, and Trp428. |
Keywords |
Marmin, Antihistamine, Ligand, Protein, Docking.
|
Citation |
Nugroho et al.
Bioinformation 9(8): 383-387 (2013) |
Edited by |
P Kangueane
|
ISSN |
0973-2063
|
Publisher |
|
License |
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License. |